Plasmid

Plasmid DNA Manufacturing Markets, 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023

The plasmid DNA manufacturing market is a dynamic and swiftly expanding sector with a crucial role in biotechnology and genetic research.

Key Points: 
  • The plasmid DNA manufacturing market is a dynamic and swiftly expanding sector with a crucial role in biotechnology and genetic research.
  • The current market landscape features the presence of over 70 companies offering a range of plasmid DNA services, including plasmid design, plasmid engineering, plasmid construction, process development and optimization, and plasmid manufacturing.
  • They are vigorously advancing their capabilities to serve as a fully integrated one-stop-shop by offering a range of plasmid services, including process development and optimization, plasmid design, plasmid engineering and plasmid construct, and GMP plasmid manufacturing.
  • Stakeholders in the plasmid manufacturing industry have forged several partnerships to enhance their service portfolios and augment the reach of their proprietary plasmid DNA technology.

AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg

Retrieved on: 
Thursday, October 12, 2023

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.
  • With this expansion and added production line, AGC Biologics can now offer more plasmid material in high-quality and GMP grades and expand the services it offers for mRNA supply.
  • The addition to the Heidelberg facility utilizes state-of-the-art single-use equipment, creating the flexibility to produce different projects simultaneously with shorter timelines and faster project turnover – allowing AGC Biologics to serve more developers in need of pDNA and mRNA materials.
  • AGC Biologics leveraged this knowledge to establish and grow its global pDNA and mRNA services at the site.

NorthX Biologics AB Announces Inauguration of Innovation Hub at Matfors Facility

Retrieved on: 
Thursday, September 28, 2023

MATFORS, Sweden, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics AB (“NorthX”) is proud to announce the official inauguration of its state-of-the-art Innovation Hub at the Matfors facility.

Key Points: 
  • MATFORS, Sweden, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics AB (“NorthX”) is proud to announce the official inauguration of its state-of-the-art Innovation Hub at the Matfors facility.
  • The Innovation Hub, co-funded by the Swedish Government, is poised to enhance the country's infrastructure for cutting-edge therapies and accelerate innovation in the biopharmaceutical sector.
  • "We are thrilled to unveil the Innovation Hub at our Matfors facility and it represents our dedication to driving innovation and progress in the field of biopharmaceuticals," said Janet Hoogstraate, CEO of NorthX Biologics AB.
  • NorthX Biologics AB extends its gratitude to all stakeholders, partners, and employees who have contributed to the realization of the Innovation Hub.

Novel Biotechnology Inc. Secures $2.5 Million in Seed Round Funding

Retrieved on: 
Wednesday, September 27, 2023

Novel Biotechnology Inc., an innovative biotechnology start-up headquartered in Canada, is pleased to announce the successful completion of its $2.5 million seed round funding.

Key Points: 
  • Novel Biotechnology Inc., an innovative biotechnology start-up headquartered in Canada, is pleased to announce the successful completion of its $2.5 million seed round funding.
  • Co-founded by CEO Pankaj Khanna and a team of accomplished serial entrepreneurs, Novel Biotechnology is on a mission to revolutionize the plasmid DNA market.
  • The proceeds from the seed round will be utilized to expand Novel's existing plasmid services business and expedite its platform R&D initiatives.
  • Congratulations, Novel Biotechnology.”
    "Due to the strong growth within the pDNA market, Novel expects robust revenue growth and profitability by FY2025," said Konstantin Rodionov, CFO & Co-Founder of Novel Biotechnology.

OBiO has launched its state-of-the-art GMP production facility Intelli-M to expedite innovative and advanced therapies to patients who are in need.

Retrieved on: 
Wednesday, September 27, 2023

OBiO has been privileged to collaborate with over 110 esteemed global clients.

Key Points: 
  • OBiO has been privileged to collaborate with over 110 esteemed global clients.
  • Meanwhile,this purpose-built facility, spanning 828,000+ square feet and equipped with 29 production lines, has officially commenced operations.
  • OBiO Technology CEO Guodong Jia said: "Currently, this industry is in a rapid development phase, characterized by intricate process development and challenging large-scale production requirements.
  • By leveraging cutting-edge and proprietary technologies, this facility expands OBIO's process development and GMP manufacturing capabilities.

Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development

Retrieved on: 
Wednesday, September 27, 2023

“Our team is relentlessly focused on developing solutions that specifically address the needs of our customers.

Key Points: 
  • “Our team is relentlessly focused on developing solutions that specifically address the needs of our customers.
  • Our latest products demonstrate our focus on addressing key bioprocessing bottlenecks and manufacturing inefficiencies during process development,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer.
  • Teknova is also introducing an extensive suite of high-quality off-the-shelf reagents to support the end-to-end plasmid workflow process, from culture media to buffers and reagents for use throughout the pDNA growth and purification process.
  • For more information about the suite of plasmid workflow solutions or to purchase them online, visit http://www.teknova.com/plasmid-workflow .

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

Retrieved on: 
Thursday, September 14, 2023

The AGCellerate LVV offering guarantees developers 1e11 total transduction units (TU) of LVV material in nine months.

Key Points: 
  • The AGCellerate LVV offering guarantees developers 1e11 total transduction units (TU) of LVV material in nine months.
  • “AGC Biologics already has one commercially approved LVV in the market and successfully concluded the PPQ campaigns of five other LVV projects.
  • By utilizing our proven platform process, AGCellerate for LVV supports developers seeking quality material on an accelerated timeline.”
    The AGCellerate LVV offering is supported by AGC Biologics’ proprietary ProntoLVV™ Platform, which offers a standardized process for full-scale development and manufacturing of viral vectors.
  • AGC’s AGCellerate program offers support for monoclonal antibodies (mAbs), LVV material, plasmid DNA (pDNA) and adeno-associated viral vectors (AAV).

AGS Therapeutics Named among Business Worldwide Magazines 20 Most Innovative Companies to Watch in 2023

Retrieved on: 
Tuesday, September 12, 2023

LONDON, Sept. 12, 2023 /PRNewswire/ -- Paris-based biopharmaceutical company AGS Therapeutics has been named by Business Worldwide Magazine in its '20 Most Innovative Companies to Watch, 2023' list.

Key Points: 
  • LONDON, Sept. 12, 2023 /PRNewswire/ -- Paris-based biopharmaceutical company AGS Therapeutics has been named by Business Worldwide Magazine in its '20 Most Innovative Companies to Watch, 2023' list.
  • Whether it's healthcare, banking, industry, construction, energy, or more, these companies are at the cutting edge of breakthrough technologies, innovation and modernized business structures.
  • Those included have a shared goal of developing revolutionary products and technology that can drive scalable business models and disrupt established industries and markets.
  • To find out more about this new approach, and what it means for patients, visit https://www.ags-tx.com
    For further information about Business Worldwide Magazine's full range of awards and company accolades, visit https://www.bwmonline.com/

AGS Therapeutics Named among Business Worldwide Magazines 20 Most Innovative Companies to Watch in 2023

Retrieved on: 
Tuesday, September 12, 2023

LONDON, Sept. 12, 2023 /PRNewswire/ -- Paris-based biopharmaceutical company AGS Therapeutics has been named by Business Worldwide Magazine in its '20 Most Innovative Companies to Watch, 2023' list.

Key Points: 
  • LONDON, Sept. 12, 2023 /PRNewswire/ -- Paris-based biopharmaceutical company AGS Therapeutics has been named by Business Worldwide Magazine in its '20 Most Innovative Companies to Watch, 2023' list.
  • Whether it's healthcare, banking, industry, construction, energy, or more, these companies are at the cutting edge of breakthrough technologies, innovation and modernized business structures.
  • Those included have a shared goal of developing revolutionary products and technology that can drive scalable business models and disrupt established industries and markets.
  • To find out more about this new approach, and what it means for patients, visit https://www.ags-tx.com
    For further information about Business Worldwide Magazine's full range of awards and company accolades, visit https://www.bwmonline.com/

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme

Retrieved on: 
Thursday, August 24, 2023

Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer.

Key Points: 
  • Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer.
  • The study is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts and is being led by Dr. David Reardon, Clinical Director, Center for Neuro-Oncology.
  • "Dosing of the first patient in the Phase 1 clinical trial of ITI-1001 in patients with GBM is a significant clinical development milestone for Immunomic, representing the first time this pDNA vaccine is being administered in humans,” stated Dr. Teri Heiland, Chief Scientific Officer of Immunomic Therapeutics.
  • For more information on the Phase 1 trial of ITI-1001 in GBM, please visit www.clinicaltrials.gov , NCT05698199